Adial Pharmaceuticals Other Current Assets Over Time

ADIL Stock  USD 1.20  0.05  4.35%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Adial Pharmaceuticals Performance and Adial Pharmaceuticals Correlation.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.
  
The value of Other Current Assets is estimated to slide to about 370.5 K.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adial Pharmaceuticals. If investors know Adial will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adial Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.94)
Return On Assets
(1.04)
Return On Equity
(3.21)
The market value of Adial Pharmaceuticals is measured differently than its book value, which is the value of Adial that is recorded on the company's balance sheet. Investors also form their own opinion of Adial Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Adial Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adial Pharmaceuticals' market value can be influenced by many factors that don't directly affect Adial Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adial Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adial Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adial Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Other Current Assets Analysis

Compare Adial Pharmaceuticals and related stocks such as Bolt Biotherapeutics, Keros Therapeutics, and Kezar Life Sciences Other Current Assets Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Days Of Payables OutstandingDividend Payout Ratio
Price To Operating Cash Flows RatioPrice To Free Cash Flows Ratio
Pretax Profit MarginEbt Per Ebit
Operating Profit MarginEffective Tax Rate
Company Equity MultiplierLong Term Debt To Capitalization
Total Debt To CapitalizationReturn On Capital Employed
Debt Equity RatioEbit Per Revenue
Quick RatioDividend Paid And Capex Coverage Ratio
Net Income Per E B TCash Ratio
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
BOLT466 K466 K466 K466 K466 K466 K466 K466 K466 K1.1 M2.5 M2.9 M3.9 M3.5 M2.6 M
KROS84 K84 K84 K84 K84 K84 K84 K84 K84 K226 K1.6 M3.2 M5.9 M15.1 M15.8 M
KZR598 K598 K598 K598 K598 K598 K598 K508 K489 KM4.4 M3.3 M9.2 M5.6 M3.4 M
REPL401 K401 K401 K401 K401 K401 K401 K763 K3.7 M2.7 M4.5 M3.3 M6.3 M8.1 M4.1 M
NVCT91 K91 K91 K91 K91 K91 K91 K91 K91 K91 K91 K91 K412 K59 K56 K
LYRA872 K872 K872 K872 K872 K872 K872 K872 K872 K311 K2.6 M4.3 M2.9 M2.1 M2.4 M
KRON315 K315 K315 K315 K315 K315 K315 K315 K315 K1.1 M5.9 MM5.5 M5.8 M4.9 M
GOSS130 K130 K130 K130 K130 K130 K130 K130 K3.1 M7.5 M9.7 M6.6 M12.4 M10.1 M7.8 M
APM1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M1.8 M14.5 M1.5 K1.4 M652.5 K3.7 M281.4 K267.4 K

Adial Pharmaceuticals and related stocks such as Bolt Biotherapeutics, Keros Therapeutics, and Kezar Life Sciences Other Current Assets description

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

My Equities

My Current Equities and Potential Positions

Adial Pharmaceuticals
ADIL
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationVirginia; U.S.A
ExchangeNASDAQ Exchange
USD 1.2
When determining whether Adial Pharmaceuticals is a strong investment it is important to analyze Adial Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Adial Pharmaceuticals' future performance. For an informed investment choice regarding Adial Stock, refer to the following important reports:
Check out Adial Pharmaceuticals Performance and Adial Pharmaceuticals Correlation.
For more information on how to buy Adial Stock please use our How to buy in Adial Stock guide.
You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Adial Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Adial Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Adial Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...